Prexasertib mesylate exhibits potent antitumor activity by inducing double-strand DNA breaks and replication stress, leading to apoptosis; it is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with potential therapeutic applications in cancer treatment.